p53 stabilization can be uncoupled from its role in transcriptional activation by loss of PTTG1/securin

Journal of Biochemistry

Volumn 141, Issue 5, 2007, Pages 737-745

  Bernal, Juan A ^a,b   Hernandez, Agustin ^a  

^a CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Calpains; Gene regulation; p53 tumour suppressor; Protein stability; PTTG1 Securin

Indexed keywords

CALPAIN; PROTEIN P53; SECURIN; UBIQUITIN;

ARTICLE; CELL STRAIN HCT116; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; STEADY STATE; TRANSCRIPTION INITIATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; CALPAIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SERINE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 34347356645     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/jb/mvm076     Document Type: Article

References (47)

1. Appella, E. and Anderson, C.W. (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772
2. Vousden, K.H. and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604
3. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U.M. (2003) p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590
4. Ferri, K.F. and Kroemer, G. (2001) Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3, 255-263
5. Blagosklonny, M.V. (1997) Loss of function and p53 protein stabilization. Oncogene 15, 1889-1893
6. Fuchs, S.Y., Adler, V., Pincus, M.R., and Ronai, Z. (1998) MERR1/JNR signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 95, 10541-10546
7. Onel, K. and Cordon-Cardo, C. (2004) MDM2 and prognosis. Mol. Cancer Res. 2, 1-8
8. Carvajal, D., Tovar, C., Yang, H., Vu, B.T., Heimbrook, D.C., and Vassilev, L.T. (2005) Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65, 1918-1924
9. Alarcon-Vargas, D. and Ronai, Z. (2002) p53-Mdm2 - the affair that never ends. Carcinogenesis 23, 541-547
10. Masdehors, P., Merle-Beral, H., Maloum, K., Omura, S., Magdelenat, H., and Delic, J. (2000) Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96, 269-274
11. Benetti, R., Del Sal, G., Monte, M., Paroni, G., Brancolini, C., and Schneider, C. (2001) The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J. 20, 2702-2714
12. Ryan, K.M., Philips, A.C., and Vousden, K.H. (2001) Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337
13. McLure, K.G. and Lee, P.W. (1998) How p53 binds DNA as a tetramer. EMBO J. 17, 3342-3350
14. Giaccia, A.J. and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes & Dev. 12, 2973-2983
15. Banin, S.L., Moyal, R., Shie, S., Taya, Y., Anderson, C.W., Chessa, L., Smorodinsky, N.I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677
16. Woo, R.A., Jack, M.T., Xu, Y., Burma, S., Chen, D.J., and Lee, P.W. (2002) DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J. 21, 3000-3008
17. Pei, L. and Melmed, S. (1997) Isolation and characterization of a pituitary tumor-transforming gene. Mol. Endocrinol. 11, 433-441
18. Domínguez, A., Ramos-Morales, F., Romero, F., Rios, R.M., Dreyfus, F., Tortolero, M., and Pintor-Toro, J.A. (1998) hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 16, 2187-2193
19. Ramos-Morales, F., Domínguez, A., Romero, F., Luna, R., Multon, M.C., Pintor-Toro, J.A., and Tortolero, M. (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19, 403-409
20. Sáez, C., Japón, M.A., Ramos-Morales, F., Romero, F., Segura, D.I., Tortolero, M., and Pintor-Toro, J.A. (1999) hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18, 5473-5476
21. Ramaswamy, S., Ross, K.N., Lander, E.S., and Galub, T.R. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54
22. Zhou, H., McGarry, T.J., Bernal, T., and Kirschner, M.W. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285, 418-422
23. Romero, F., Multon, M.C., Ramos-Morales, F., Domínguez, A., Bernal, J.A., Pintor-Toro, J.A., and Tortolero, M. (2001) Human securin, hPTTG, is associated with Ru heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucl. Acids Res. 29, 1300-1307
24. Bernal, J.A., Luna, R., Espina, A.́, Lázaro, I., Ramos-Morales, F., Romero, F., Arias, C., Silva, A., Tortolero, M., and Pintor-Toro, J.A. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet. 32, 306-311
25. Masramon, L., Ribas, M., Cifuentes, P., Arribas, R., Garcia, F., Egozcue, J., Peinado, M.A., and Miro, R. (2000) Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet. Cytogenet. 121, 17-21
26. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, R.W., and Volgestein, B. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501
27. Lengauer, C., Kinzler, K.W., and Volgestein, B. (1997) Genetic instability in colorectal cancers. Nature 386, 623-627
28. Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734
29. Jallepalli, P.V., Waizenegger, I.C., Bunz, F., Langer, S., Speicher, M.R., Peters, J.M., Kinzler, K.W., Volgestein, B., and Lengauer, C. (2001) Securin is required for chromosomal stability in human cells. Cell 105, 445-457
30. Pfleghaar, K., Heubes, S., Cox, J., Stemmann, O., and Speicher, M.R. (2005) Securin is not required for chromosomal stability in human cells. PLoS Biol 3, 2127-2134
31. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow, E. (1993) Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes & Devel. 7, 1111-1125
32. Bradford, M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
33. Collis, S.J., De Weese, T.L., Jeggo, P.A., and Parker, A.R. (2005) The life and death of DNA-PR. Oncogene 24, 949-961
34. Shao, R.G., Cao, C.X., Zhang, H., Kohn, K.W., Wold, M.S., and Pommier, Y. (1999) Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18, 1397-1406
35. Craig, A.L., Burch, L., Vojtesek, B., Mikutowska, J., Thompson, A., and Hupp, T.R. (1999) Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342, 133-141
36. Dai, M.S. and Lu, H. (2004) Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475-44482
37. Li, Z., Ortega-Vilain, A.C., Patil, G.S., Chu, D.L., Foreman, J.E., Eveleth, D.D., and Powers, J.C. (1996) Novel peptidyl a-keto amide inhibitors of calpains and other cysteine proteases. J. Med. Chem. 39, 4089-4098
38. Raser, K.J., Posner, A., and Wang, K.K. (1995) Casein zymography: a method to study μ-calpain, m-calpain, and their inhibitory agents. Arch. Biochem. Biophys. 319, 211-216
39. Pariat, M., Carillo, S., Molinari, M., Salvat, C., Debussche, L., Bracco, L., Milner, J., and Piechaczyk, M. (1997) Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell Biol. 17, 2806-2815
40. Dong, Y.N., Waxman, E.A., and Lynch, D.R. (2004) Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit control calpain-mediated cleavage of the NMDA receptor. J. Neurosci. 24, 11035-11045
41. Seubert, P., Baudry, M., Dudek, S., and Lynch, G. (1987) Calmodulin stimulates the degradation of brain spectrin by calpain. Synapse 1, 20-24
42. Shie, S.-Y., Ikeda, M., Taya, Y., and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334
43. Dumaz, N. and Meek, D.W. (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18, 7002-7010
44. Chao, J.I., Hsu, S.H., and Tsou, T.C. (2006) Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway. Toxicol. Sci. 90, 73-86
45. Chiu, S.J., Hsu, T.S., and Chao, J.I. (2006) Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol. Lett. 167, 122-130
46. Cho-Rok, J., Yoo, J., Jang, Y.J., Kim, S., Chu, I.S., Yeom, Y.I., Choi, J.Y., and Im, D.S. (2006) Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 43, 1042-1052
47. Shah, R. and El-Deiry, W.S. (2004) p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol. Ther. 3, 871-875